Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99,605,545
-
Number of holders
-
221
-
Total 13F shares, excl. options
-
95,978,123
-
Shares change
-
+1,238,497
-
Total reported value, excl. options
-
$5,879,367,235
-
Value change
-
+$103,870,885
-
Put/Call ratio
-
62%
-
Number of buys
-
127
-
Number of sells
-
-78
-
Price
-
$61.28
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q3 2017
267 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q3 2017.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 221 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95,978,123 shares
of 99,605,545 outstanding shares and own 96.4% of the company stock.
Largest 10 shareholders include FMR LLC (13,233,030 shares), PRICE T ROWE ASSOCIATES INC /MD/ (7,207,373 shares), VANGUARD GROUP INC (7,023,442 shares), JANUS HENDERSON GROUP PLC (5,507,763 shares), BlackRock Inc. (4,857,118 shares), PERCEPTIVE ADVISORS LLC (4,791,589 shares), WELLINGTON MANAGEMENT GROUP LLP (3,695,109 shares), BB BIOTECH AG (3,462,753 shares), FRANKLIN RESOURCES INC (3,265,615 shares), and Invesco Ltd. (2,949,868 shares).
This table shows the top 221 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.